Machine learning links a three-gene lung-cancer score to retrospective survival differences
Source check: Source checked. Not independent scientific confirmation.
Finding: LASSO and random-forest selection identified a three-gene lung-adenocarcinoma score associated with observed survival in public cohorts. Comparison cohorts showed limited and inconsistent discrimination: TCGA five-year AUC was approximately 0.50, while another cohort reached approximately 0.68. This supports a bounded retrospective association, without established clinical utility or causal gene effects.
Technology: LASSO and random forests for prognostic gene selection; consensus clustering for RAS expression subtypes
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Learned LASSO and random-forest feature selection produced the three-gene signature whose relationship with measured patient survival was evaluated across cohorts. General clustering benchmarks and untested drug predictions are not the admitted finding.
- Test and result
- The source reports 624 GEO lung-adenocarcinoma profiles used for derivation. LASSO with ten-fold cross-validation and random-forest feature selection intersected at MAPK10, PLA2G12B and SHC3. The resulting score was compared with observed survival in TCGA and GSE13213. Reported one-, three- and five-year AUCs were 0.608, 0.535 and 0.496 in TCGA, and 0.620, 0.654 and 0.682 in GSE13213.
- Limitation / still unknown
- Outcome-optimized risk cutoffs limit interpretation of group survival differences as locked external prediction. Exact cohort eligibility accounting and supplementary implementation were not reconstructed. Weak TCGA discrimination limits clinical claims; decision-curve calculations do not demonstrate actual patient benefit. Transcriptomic associations and drug predictions do not establish causal mechanisms or treatment efficacy. Original online date is May 28, 2026; the assigned December issue is later.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1007/s12672-026-05282-9
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Read actual primary cohort acquisition, consensus clustering, gene selection, LASSO/random-forest and risk-score evaluation Methods, cohort survival/AUC Results and limitations. Supplementary code and individual-patient eligibility were not independently reconstructed. Exact original article front DOI/title and fresh PubMed primary relationship metadata checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.